A$37.60 pre-market for ResMed (RMD.AX): Jan 29 earnings to shape guidance
ResMed Inc. (RMD.AX) trades at A$37.60 in pre-market trade on 28 Jan 2026 as investors position ahead of the company’s Jan 29, 2026 earnings release. RMD.AX stock faces a test on growth and margins with consensus expecting revenue near US$1.39bn and EPS around US$2.68 for the quarter. Market focus will be on mask resupply strength, device demand and software subscription momentum as the report can swing sentiment into the ASX trading session.
RMD.AX stock: pre-earnings snapshot
ResMed (RMD.AX) is trading at A$37.60 with a day range A$37.08–A$37.95 and volume 1,193,170 shares. The stock’s 50-day average is A$37.62 and the 200-day average is A$39.48, indicating short-term consolidation near recent mean levels.
RMD.AX stock: what the Jan 29 earnings will reveal
Analysts expect the fiscal Q2 report to show EPS of US$2.68 and revenue near US$1.39bn, driven by mask resupply and device sales. Investors should watch reported growth in Masks and Devices and any updates to Software-as-a-Service guidance, which can shift near-term multiples.
RMD.AX stock: fundamentals and valuation
ResMed shows trailing EPS 1.41 and a PE of 26.67 on ASX pricing, with market cap about A$54.88 billion and shares outstanding 1.46 billion. The company’s PB ratio is 0.62 and current ratio 2.89, reflecting strong liquidity. Compared with the Healthcare sector average PE 34.06, RMD.AX stock trades at a relative valuation discount on earnings multiples.
RMD.AX stock: technicals and market context
Momentum indicators are neutral: RSI 48.63 and MACD slightly negative. Bollinger Bands centre sits at A$37.05 with upper A$38.63 and lower A$35.46, suggesting limited immediate volatility. Sector flows in healthcare have been muted, with the ASX healthcare group showing modest YTD performance.
RMD.AX stock: Meyka AI grade and model forecast
Meyka AI rates RMD.AX with a score of 76.45 out of 100 (B+, BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month price of A$44.22, versus the current A$37.60, implying an upside of 17.61%. Forecasts are model-based projections and not guarantees.
RMD.AX stock: risks and near-term catalysts
Primary near-term catalysts are the Jan 29 earnings print, commentary on device inventory and mask resupply, and updates on Software-as-a-Service margins. Key risks include weaker-than-expected resupply, regulatory setbacks in device rollouts, and currency translation pressures given ResMed’s global footprint.
Final Thoughts
Key takeaways for RMD.AX stock ahead of the Jan 29 earnings: ResMed is trading at A$37.60 with liquidity comfortable and a PE of 26.67, below the sector average. Earnings expectations show moderate top-line growth driven by masks and devices while software remains a margin lever. Meyka AI’s model projects A$44.22 in 12 months, an implied upside of 17.61% versus today’s price, while a conservative near-term price target of A$41.50 and a bull case of A$50.00 frame reasonable scenarios depending on guidance. Remember that forecast figures are model projections, not guarantees. Watch guidance on subscription revenue and mask resupply for tradeable moves when results arrive; these items historically drive the most immediate price response. For full company filings and prior-quarter detail see the Nasdaq preview and MarketBeat coverage linked below and the Meyka AI stock page for live updates and real-time signals.
FAQs
When does ResMed report earnings and why does it matter for RMD.AX stock?
ResMed reports on 29 Jan 2026 after markets close. The report matters because it updates device and mask sales, software revenue and guidance. These items directly affect RMD.AX stock valuation and near-term trading on the ASX.
What is Meyka AI’s price forecast for RMD.AX stock?
Meyka AI’s forecast model projects A$44.22 for the next 12 months versus the current A$37.60, implying a 17.61% upside. Forecasts are model-based projections and not guarantees.
Which metrics should investors watch in ResMed’s earnings?
Focus on Masks and Devices revenue growth, Software-as-a-Service monthly recurring revenue and margin trends, EPS vs consensus, and management guidance. These metrics typically drive immediate moves in RMD.AX stock.
How is ResMed valued compared to the healthcare sector?
ResMed’s PE near 26.67 sits below the ASX healthcare average PE of 34.06, indicating a relative earnings multiple discount despite robust margins and free cash flow metrics for RMD.AX stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
